Oct 21 (Reuters) - Inovio Pharmaceuticals Inc :
* INOVIO ANNOUNCES NEW DATA AT SCIENTIFIC CONFERENCES FOR LEAD CANDIDATE, INO-3107, AS A POTENTIAL TREATMENT FOR RRP
* INOVIO PHARMACEUTICALS INC - INO-3107 WELL TOLERATED, 81% OF PATIENTS REQUIRED FEWER SURGERIES POST-TREATMENT
* INOVIO PHARMACEUTICALS INC - 81% OF PATIENTS EXPERIENCED FEWER SURGICAL INTERVENTIONS POST-TREATMENT WITH INO-3107
* INOVIO PHARMACEUTICALS INC - INO-3107 WELL TOLERATED, MOST FREQUENT AES WERE INJECTION SITE PAIN AND FATIGUE
Source text for Eikon: Further company coverage:
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。